Back to search
FDAFDA · Food and drugs·Recall number D-0265-2022

5% Dextrose Injection, USP, 50 mL ADD-Vantage Unit, Rx only, Distributed by Hospira, INC., Lake Forest, IL 60045 USA, NDC 0409-7100-68/0409-7100-66

Published December 8, 2021 · Recall initiated: November 30, 2021

Summary

FDA records drug Class II recall D-0265-2022, published December 8, 2021 and initiated November 30, 2021. Recalling firm: Pfizer Inc.; Status: Terminated; Reported quantity: 765 bags; Lot: Lot: 4923608 Exp. 1MAY2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of sterility assurance: bag has the potential to leak.

What to do

Voluntary: Firm initiated · Letter

Get an email if DEXTROSE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
DEXTROSE
Manufacturer
Pfizer Inc.
Distributor
USA Nationwide
Lot
Lot: 4923608 Exp. 1MAY2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was 5% Dextrose Injection, USP, 50 mL ADD-Vantage Unit, Rx only, Distributed by Hospira, INC., Lake Forest, IL 60045 USA, NDC 0409-7100-68/0409-7100-66 recalled?

Yes. FDA published recall D-0265-2022 on December 8, 2021. Reported hazard: Lack of sterility assurance: bag has the potential to leak.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: DEXTROSE.